Alcami Corp. on Thursday announced that it will invest $2 million investment at its Wilmington site.
Officials with the contract development and manufacturing organization said in a news release that the investment will expand its oral solid development and manufacturing capabilities at the local site.
The Wilmington facility, 2320 Scientific Park Drive, is specialized to manufacture oral solid dosage forms and supports Alcami's "preclinical production through commercial launch and supply," according to the company, which works with biologics and pharmaceutical companies.
With the $2 million, Alcami plans to add a "Gerteis Mini-Pactor roller compactor and low humidity suites" to its existing 140,000-square-foot Wilmington campus, stated the release. The work will also add dry granulation capabilities and "increased flexibility to support moisture-sensitive processes."
"Alcami’s cGMP oral solid manufacturing technologies are arranged in flexible suites designed for novel, advanced, and complex projects," the release stated. "Embedded within the manufacturing facility, in-house formulation development and analytical experts offer drug innovators co-located product development, optimization, scale-up, and life cycle management."
Officials are looking to finish the work in the first half of this year.
The company continues to grow and add jobs in the area. Alcami currently has 21 open positions in the Wilmington area, said marketing manager Michael Walsh.
"We are pleased to support our customers’ clinical to small scale commercial supply needs with modern, flexible, and reliable capacity,” Walt Kaczmarek, CEO of Alcami, said in the release. “Our investment in Wilmington is another step in our continued growth strategy to become the preferred provider of drug product and analytical services in the pharmaceutical industry.”